Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Proton pump inhibitors (PPIs) are the cornerstone in the treatment of gastresophageal reflux disease (GORD). PPIs are metabolized by the hepatic cytochrome P-450 enzymes (CYP-450). Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs. In this study we evaluated the influence of rabeprazole administration on hepatic CYP-450 activity as measured by the 13C-aminopyrine breath test (13C-ABT) in a group of patients with GORD. 13C-ABT was performed on five GORD patients both before and after 1 week of rabeprazole administration (20 mg, b.i.d.). Pretreatment 13C-ABT results were compared to posttreatment results. Pre- and posttreatment 13C-ABT results for patients were compared to those obtained in five controls who did the test twice, with a 1-week interval in between. Before treatment, the 13C-ABT results for the GORD patients did not significantly differ from those of healthy subjects. After treatment, we observed no significant modification of the 13C-ABT in GORD patients compared to pretreatment values (13C-ABT %dose/hr, 10.56±1.31 versus 11.17±0.88; 13C-ABT %cumulative dose, 8.08±1.11 versus 8.34±0.56). Posttreatment 13C-ABT results were not significantly different from those obtained in controls at weekly repetition of the test. In patients with GORD, 1-week, full-dose rabeprazole does not display any significant interactions with CYP-450 activity.

Original languageEnglish
Pages (from-to)1602-1606
Number of pages5
JournalDigestive Diseases and Sciences
Volume51
Issue number9
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Rabeprazole
Aminopyrine
Breath Tests
Cytochrome P-450 Enzyme System
Proton Pump Inhibitors
Therapeutics
Liver
Healthy Volunteers

Keywords

  • C-aminopyrine breath test
  • Liver function
  • Rabeprazole

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease. / Giannini, Edoardo G.; Savarino, Vincenzo; Testa, Roberto.

In: Digestive Diseases and Sciences, Vol. 51, No. 9, 09.2006, p. 1602-1606.

Research output: Contribution to journalArticle

@article{e592f54e01a448c9a406dbad48d3cbe5,
title = "Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease",
abstract = "Proton pump inhibitors (PPIs) are the cornerstone in the treatment of gastresophageal reflux disease (GORD). PPIs are metabolized by the hepatic cytochrome P-450 enzymes (CYP-450). Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs. In this study we evaluated the influence of rabeprazole administration on hepatic CYP-450 activity as measured by the 13C-aminopyrine breath test (13C-ABT) in a group of patients with GORD. 13C-ABT was performed on five GORD patients both before and after 1 week of rabeprazole administration (20 mg, b.i.d.). Pretreatment 13C-ABT results were compared to posttreatment results. Pre- and posttreatment 13C-ABT results for patients were compared to those obtained in five controls who did the test twice, with a 1-week interval in between. Before treatment, the 13C-ABT results for the GORD patients did not significantly differ from those of healthy subjects. After treatment, we observed no significant modification of the 13C-ABT in GORD patients compared to pretreatment values (13C-ABT {\%}dose/hr, 10.56±1.31 versus 11.17±0.88; 13C-ABT {\%}cumulative dose, 8.08±1.11 versus 8.34±0.56). Posttreatment 13C-ABT results were not significantly different from those obtained in controls at weekly repetition of the test. In patients with GORD, 1-week, full-dose rabeprazole does not display any significant interactions with CYP-450 activity.",
keywords = "C-aminopyrine breath test, Liver function, Rabeprazole",
author = "Giannini, {Edoardo G.} and Vincenzo Savarino and Roberto Testa",
year = "2006",
month = "9",
doi = "10.1007/s10620-005-9035-7",
language = "English",
volume = "51",
pages = "1602--1606",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease

AU - Giannini, Edoardo G.

AU - Savarino, Vincenzo

AU - Testa, Roberto

PY - 2006/9

Y1 - 2006/9

N2 - Proton pump inhibitors (PPIs) are the cornerstone in the treatment of gastresophageal reflux disease (GORD). PPIs are metabolized by the hepatic cytochrome P-450 enzymes (CYP-450). Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs. In this study we evaluated the influence of rabeprazole administration on hepatic CYP-450 activity as measured by the 13C-aminopyrine breath test (13C-ABT) in a group of patients with GORD. 13C-ABT was performed on five GORD patients both before and after 1 week of rabeprazole administration (20 mg, b.i.d.). Pretreatment 13C-ABT results were compared to posttreatment results. Pre- and posttreatment 13C-ABT results for patients were compared to those obtained in five controls who did the test twice, with a 1-week interval in between. Before treatment, the 13C-ABT results for the GORD patients did not significantly differ from those of healthy subjects. After treatment, we observed no significant modification of the 13C-ABT in GORD patients compared to pretreatment values (13C-ABT %dose/hr, 10.56±1.31 versus 11.17±0.88; 13C-ABT %cumulative dose, 8.08±1.11 versus 8.34±0.56). Posttreatment 13C-ABT results were not significantly different from those obtained in controls at weekly repetition of the test. In patients with GORD, 1-week, full-dose rabeprazole does not display any significant interactions with CYP-450 activity.

AB - Proton pump inhibitors (PPIs) are the cornerstone in the treatment of gastresophageal reflux disease (GORD). PPIs are metabolized by the hepatic cytochrome P-450 enzymes (CYP-450). Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs. In this study we evaluated the influence of rabeprazole administration on hepatic CYP-450 activity as measured by the 13C-aminopyrine breath test (13C-ABT) in a group of patients with GORD. 13C-ABT was performed on five GORD patients both before and after 1 week of rabeprazole administration (20 mg, b.i.d.). Pretreatment 13C-ABT results were compared to posttreatment results. Pre- and posttreatment 13C-ABT results for patients were compared to those obtained in five controls who did the test twice, with a 1-week interval in between. Before treatment, the 13C-ABT results for the GORD patients did not significantly differ from those of healthy subjects. After treatment, we observed no significant modification of the 13C-ABT in GORD patients compared to pretreatment values (13C-ABT %dose/hr, 10.56±1.31 versus 11.17±0.88; 13C-ABT %cumulative dose, 8.08±1.11 versus 8.34±0.56). Posttreatment 13C-ABT results were not significantly different from those obtained in controls at weekly repetition of the test. In patients with GORD, 1-week, full-dose rabeprazole does not display any significant interactions with CYP-450 activity.

KW - C-aminopyrine breath test

KW - Liver function

KW - Rabeprazole

UR - http://www.scopus.com/inward/record.url?scp=33748617165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748617165&partnerID=8YFLogxK

U2 - 10.1007/s10620-005-9035-7

DO - 10.1007/s10620-005-9035-7

M3 - Article

C2 - 16927149

AN - SCOPUS:33748617165

VL - 51

SP - 1602

EP - 1606

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 9

ER -